Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study

INTRODUCTION: Pimavanserin is approved in the USA to treat hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). OBJECTIVES: We evaluated mortality in patients with PDP after initiation of pimavanserin or comparator atypical antipsychotics, overall, over time, and across...

Descripción completa

Detalles Bibliográficos
Autores principales: Layton, J. Bradley, Forns, Joan, McQuay, Lisa J., Danysh, Heather E., Dempsey, Colleen, Anthony, Mary S., Turner, Mary Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883317/
https://www.ncbi.nlm.nih.gov/pubmed/36517664
http://dx.doi.org/10.1007/s40264-022-01260-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883317/
https://www.ncbi.nlm.nih.gov/pubmed/36517664
http://dx.doi.org/10.1007/s40264-022-01260-6

Ejemplares similares